“Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer”, ADMET DMPK, vol. 4, no. 4, pp. 314–326, Dec. 2016, doi: 10.5599/admet.4.4.341.